EV/EBITDA Multiple: AmerisourceBergen (COR)

Graphic logo of AmerisourceBergen (COR)

The EV/EBITDA ratio for Cencora, Inc. (COR) on the GURU.Markets intraday time-series chart demonstrates stability, with the 12.77 mark reflecting the current state. Growth is driven by the company's status as a logistics oligopolist with an unreachable scale. Revenues are based on mass pharmaceutical supplies to hospitals and pharmacies. Stephen Collis's flawless management guarantees investors operational resilience and effective margin control.

COR Cencora Inc: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/11/2026

COR (cencora.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price AmerisourceBergen|COR - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization AmerisourceBergen Corporation|COR - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Cencora|COR - Accounting Capitalization|Market Capitalization to Book Value Ratio cencora.com|COR - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Cencora, Inc.|COR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Cencora|COR - Aggregate Debt Obligations|Debts to Book Capitalization AmerisourceBergen Corporation|COR - Company Long-Term Debts|Company Current Liabilities Cencora|Quick Ratio cencora.com
- business earnings and investment ratios data:
COR - Net Financial Result|Expected Profit Cencora, Inc.|COR - Price to Earnings Multiple|Forward P/E Multiple Cencora, Inc.|COR - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio AmerisourceBergen Corporation|COR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Cencora|COR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months cencora.com|COR - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Cencora, Inc.
Summary company analysis:AmerisourceBergen COR
Original product of Cencora

The analyst assesses the resilience of Cencora, Inc. (COR) to market shocks through the lens of its debt load. The stability of the business is underpinned by the critical role of pharmaceutical logistics within the healthcare system. The business valuation based on the EV/EBITDA multiple relates the company's total value to its operating profit before taxes, depreciation, and amortization. A downward trend in the curve signals that the asset is undervalued, provided that the fundamental efficiency of distribution remains unchanged.

Competitors of Cencora, Inc.

EV/EBITDA Multiple CVS (CVS Health)|MCK - Enterprise Value to EBITDA Ratio|Cardinal Health, Inc. - EV/EBITDA Multiple|Company Value to EBITDA henryschein.com|Prestige Consumer Healthcare, Inc. (PBH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation WGRX|YI (111, Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Jiuzhou 360 (RDGT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Universe Pharmaceuticals (UPC)|BDRX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Hong Kong Pharma Digital Limited HKPD|Business Value to Operating Income Before Depreciation BIMI|Jiuzhou 360 - EV/EBITDA Multiple|WBA - EV/EBITDA Multiple